Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | MIF | P14174 | 8/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 7/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929861 | 0.92 | KCNH2 (0.51) | KCNH2MIFF10NPC1RAB9A | |
| SCHEMBL9968567 | 0.91 | KCNH2 (0.41) | KCNH2MIFF10IRAK4 | |
| SCHEMBL9968506 | 0.90 | KCNH2 (0.39) | KCNH2MIFHDAC6F10RAB9A | |
| SCHEMBL9968481 | 0.90 | MAOB (0.38) | KCNH2MIFF10IRAK4MAOA | |
| SCHEMBL9964770 | 0.88 | KCNH2 (0.51) | KCNH2MIFF10MAOAMAOB | |
| SCHEMBL9968492 | 0.87 | MIF (0.38) | KCNH2MIFHDAC6F10IRAK4 | |
| SCHEMBL9968491 | 0.86 | KCNH2 (0.42) | KCNH2F10 | |
| SCHEMBL14069358 | 0.85 | KCNH2 (0.42) | KCNH2MIF | |
| SCHEMBL9968582 | 0.84 | KCNH2 (0.48) | KCNH2F10MAOAMAOBCYP2C19 | |
| SCHEMBL9929978 | 0.84 | KCNH2 (0.39) | KCNH2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | KCNH2 1295/4885MIF 852/4885HDAC6 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.